Analysis on Medication Rules of Using Chinese Medicine in Reducing Recurrence and Metastasis of Stage II and III Colorectal Cancer among Postoperative Patients
10.11842/wst.2014.01.004
- VernacularTitle:中医药减少Ⅱ、Ⅲ期结直肠癌根治术后复发转移的用药规律分析
- Author:
Xin DU
;
Yufei YANG
;
Yun XU
;
Jianbin WANG
- Publication Type:Journal Article
- Keywords:
Yang Yufei;
stage II and III colorectal cancer;
medication rules;
recurrence and metastasis;
Chinese medicine treatment;
follow-up
- From:
World Science and Technology-Modernization of Traditional Chinese Medicine
2014;(1):21-26
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to analyze the living status and medication rules of traditional Chinese medicine (TCM) treatment of postoperative patients with stage II and III colorectal cancer by Prof. Y ang Y ufei. A total of 70 postoperative patients with stage II and III colorectal cancer were enrolled in the cohort study at the Xiyuan Hospital from September 2007 to August 2009. The out-patient records were reviewed and follow-ups were given for the analysis. The results showed that until July 2013, the loss to follow-up rate was 8.6%, which was less than 15%. The four-year postoperative recurrence and metastasis rates of the high and low exposure group were 7.1% and 25.0%, respectively. The Fisher exact probability test showed that the high exposure and long period therapy of TCM treatment can significantly reduce the recurrence and metastasis rate of patients (P < 0.05). The analysis of Prof. Y ang Y ufei's medication rules in TCM treatment of postoperative colorectal cancer showed that the syndrome differ-entiation pattern with the highest frequency was spleen-stomach deficiency pattern; and the liver-kidney yin defi-ciency pattern was in the second place. The prescriptions used with the highest frequency were Si-Jun-Zi Decoction and Liu-Wei-Di-Huang Decoction. It was concluded that the comprehensive TCM treatment can improve the prog-nosis of stage II and III colorectal cancer. The treatment also has certain meaning in the reducing of the recurrence and metastasis rate of patients, and prolonging the time of the recurrence and metastasis.
